Vilazodone: A brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor

Therapeutic Advances in Psychopharmacology

Volumn 1, Issue 3, 2011, Pages 81-87

  Schwartz, Thomas L ^a   Siddiqui, Umar A ^a   Stahl, Stephen M ^b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antidepressant; major depressive disorder; serotonin; vilazodone

Indexed keywords

CYTOCHROME P450 3A4; SEROTONIN; VILAZODONE;

ARTICLE; DIARRHEA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; MAJOR DEPRESSION; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; REFRACTORY PERIOD; SOMNOLENCE; TREATMENT DURATION; XEROSTOMIA;

EID: 84997941890     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125311409486     Document Type: Article

References (36)

1. Adamec R. Bartoszyk G. Burton P. (2004) Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol 504: 65–77.
2. APA. (2000) American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th edn text revision Washington, DC: American Psychiatric Publishing.
3. APA (2010) American Psychiatric Association practice guideline for major depressive disorder in adults. Am J Psychiatry 150: 1–26.
4. Barowsky J. Schwartz T.L. (2006) An evidence based approach to augmentation and combination strategies for treatment resistant depression. Psychiatry (Edgmont) 3: 42–61.
5. Bartoszyk G.D. Hegenbart R. Ziegler H. (1997) EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol 322: 147–153.
6. Blier P. Ward H.E. Tremblay P. Laberge L. Hébert C. Bergeron R. (2010) Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 167: 281–288.
7. Corya S.A. Perlis R.H. Keck P.E. Jr Lin D.Y. Case M.G. Williamson D.J. et al. (2006) A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry 67: 798–806.
8. Dawson L.A. Watson J.M. (2009) Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Thera 15: 107–117.
9. Duxon M.S. Starr K.R. Upton N. (2000) Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT1A receptor antagonist WAY100635. Br J Pharmacol 130: 1713–1719.
10. Forest Pharmaceuticals (2011) Vilazodone FDA Package Insert, New York, USA.
11. Heinrich T. Bottcher H. Gericke R. Bartoszyk G.D. Anzali S. Seyfried C.A. et al. (2004) Synthesis and structure–activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J Med Chem 47: 4684–4692.
12. Hogg S. Dalvi A. (2004) Acceleration of onset of action in schedule-induced polydipsia: combinations of SSRI and 5-HT1A and 5-HT 1B receptor antagonists. Pharmacol Biochem Behav 77: 69–75.
13. Hudziak J. Waterman C.S. In: Kaplan and Sadock's comprehensive textbook of psychiatry. (Sadock B.J. Sadock V.A. (Eds.) (2005) Buspirone (8th edn). Philadelphia, New York: Lipincott Williams & Wilkins.
14. Hughes Z.A. Starr K.R. Langmead C.J. Hill M. Bartoszyk G.D. Hagan J.J. et al. (2005) Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 510: 49–57.
15. Khan, A., Cutler, A.J., Kajdasz, D.K., Gallipoli, S, Athanasiou, M, Robinson, D.S. et al. (2011) A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder. J Clin Psychiatry 72: 441–447.
16. Murck H. Frieboes R.M. Antonijevic I.A. Steiger A. (2001) Distinct temporal pattern of the effects of the combined serotonin-re-uptake inhibitor and 5-HT1A agonist EMD 68843. Psychopharmacology 155: 187–192.
17. Othmer E. Othmer S.C. (1987) Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. J Clin Psychiatry 48: 201–203.
18. Page M.E. Cryan J.F. Sullivan A. Dalvi A. Saucy B. Manning D.R. et al. (2002) Behavioral and neurochemical effects of 5-{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperaziny}-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine1A receptor partial agonist. J Pharmacol Exp Ther 302: 1–8.
19. Pellow S. Chopin P. File S.E. Briley M. (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Method 14: 149–167.
20. Pies R. (1998) Handbook of Essential Psychopharmacology Washington, DC: American Psychiatric Press Inc.
21. Rabiner E.A. Gunn R.N. Wilkins M.R. Sargent P.A. Mocaer E. Sedman E. et al. (2000) Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. Nucl Med Biol 27: 509–513.
22. Rickels K. Athanasiou M. Robinson D.S. Gibertini M. Whalen H. Reed C.R. (2009) Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 70: 326–333.
23. Roberts C. Hagan J.J. Bartoszyk G.D. Kew J.N. (2005) Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus. Eur J Pharmacol 517: 59–63.
24. Rush A. (2010) Combining antidepressant medications: a good idea? Am J Psychiatry 167: 241–243.
25. Rush A.J. Trivedi M.H. Wisniewski S.R. Nierenberg A.A. Stewart J.W. Warden D. et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905–1917.
26. Schwartz T.L. Rashid A. (2007) Augmentation and Combination Pharmacotherapy trends in major depressive disorder: results of a brief survey of psychiatrists. P&T 32: 28–31.
27. Schwartz T.L. and Stah, S.M. (2010) Optimizing Antidepressant Management of Depression: current Status and Future Perspectives Vol. 27, 9th edn. Basel: Karger, 254–267.
28. Sorbera L.A. and Rabasseda, X. Silvestre J. Castaner J. (2001) Vilazodone hydrochloride–antidepressant–5-HT1A partial agonist–5-HT reuptake inhibitor. Drugs Future 26: 247–252.
29. Stahl S. (2008) Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 3rd edn Cambridge: Cambridge University Press.
30. Stahl S. (2009) Combining antidepressant therapies from the initiation of treatment: a paradigm shift for major depression. J Clin Psychiatry 70: 1493–1494.
31. Stahl S. (2010) Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectrums 15: 79–94.
32. Stahl S. (2011) Essential Psychopharmacology: the Prescriber's Guide, 4th edn Cambridge: Cambridge University Press.
33. Treit D. (1990) A comparison of anxiolytic and nonanxiolytic agents in the shock-probe burying test for anxiolytics. Pharmacol Biochem Behav 36: 203–205.
34. Treit D. Menard J. Royan C. (1993) Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44: 463–469.
35. Trivedi M.H. Fava M. Wisniewski S.R. Thase M.E. Quitkin F. Warden D. for the STAR*D Study Team et al. (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354: 1243–1252.
36. Weisler R. Joyce M. McGill L. Lazarus A. Szamosi J. Eriksson H. Moonstone Study Group (2009) Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 14: 299–313.